Danish biopharmaceutical firm Zealand Pharma has announced that its partner Sanofi has submitted a marketing authorisation application for Lyxumia (lixisenatide) in Europe.
Lixisenatide, developed by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for type 2 diabetes.
Go deeper with GlobalData
Sanofi is set to complete the Phase III development of the drug as a new treatment for the disease.
The marketing authorisation application includes data from the GetGoal Phase III programme, comprising nine studies involving over 4,300 patients.
The trial is intended to provide data for supporting lixisenatide as a treatment for type 2 diabetes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
